Research opportunity

Investigating the occurrence of food sensitivity and the relationship with gut microbiome in Angelman syndrome could lead to dietary intervention to help to reduce or alleviate symptoms

Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome

Two press releases were issued recently with one announcing an Exclusive Option Agreement between GeneTx Biotherapeutics, LLC (“GeneTx”) and Ultragenyx Pharmaceutical, Inc. (“Ultragenyx”), and the other announcing GeneTx’s lead candidate receiving Orphan Drug Designation (ODD) and Rare Pediatric Drug Designation (RPD). GeneTx would like to take this opportunity to provide additional information to our community about this very exciting news.

New Board Member

Felicity Williams joins the FAST board. Felicity’s combination of medical knowledge and position as a parent will be a asset to our team.

Murdoch Fellowship

FAST Australia announces a new two-year Angelman syndrome research fellowship for Dr Emma Baker at the Murdoch Children’s Research Institute.